JPRN-UMIN000011570
Recruiting
未知
The assessment of the response to everolimus of renal cell carcinoma by FDG PET/CT and its impact on prognosis - FDG-PET/CT assessment of response to everolimus in renal cell carcinoma
Conditionsadvanced renal cell carcinoma (RCC)
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- advanced renal cell carcinoma (RCC)
- Sponsor
- Yokohama City University
- Enrollment
- 30
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients who meet any of the following are excluded from the study. (1\)Concurrent antitumor treatment other than everolimus is given. (2\)Prior treatment with more or 2 tyrosine kinase inhibitors (3\)Prior treatment of treatment with mTOR inhibitors (temsirolimus or everolimus) (4\)Prior treatment with chemotherapy with antitumor drug, regardless of cytokine therapy (5\)Poorly\-controlled diabetes mellitus (fasting blood glucose more than 150 g/dL) (6\)Pregnant and/or nursing woman, possibility of pregnancy (7\)History of organ transplantation (including bone marrow transplantation) (8\)History of malignancy except: (i)Curatively treated intraepithelial cervical cancer, basal cell carcinoma, superficial bladder cancer (Ta, Tis and T1\). (ii)Patients who had been disease free more for than 3 years after curative therapy
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Introduction of everolimus is associated with a reduction in the dosage of calcineurine-inhibitors in patients with a pulmonary graft who suffer from a notable chronic renal insuffisance.Patient who received a pulmonary transplant and who show notable renale insuffisance (DFG < 50ml/min/1.73m²) which has been progressive over the last two years or chronical renal insuffisance which progresses fast (a los of >50% DGF in 3 months) and isotopical glomerural filtration < 45 ml/min.EUCTR2006-001945-32-BEB Erasme15
Recruiting
Not Applicable
Clinical effects of everolimus in the subjects with autism spectrum disprders (ASD) in relation to tuberous sclerosis.there are a few individuals with TSC with SEGA who exhibite ASD symptoms.JPRN-jRCT1090220258Kunio Yui20
Completed
Not Applicable
Assessment of efficy and safety of everolimus in Japanese patients with mRCCrenal cell carcinomaJPRN-UMIN000009620Tokyo Afinitor Clinical Trial Group200
Recruiting
Phase 2
Efficacy of 0.05%topical everolimus in the treatment of adenoma sebaceum in tuberous sclerosisadenoma sebaceumTCTR20180820002Dermatology division, Department of internal medicine, King Chulalongkorn Memorial Hospital15
Active, not recruiting
Not Applicable
Everolimus and Fulvestrant therapy in postmenopausal metastatic Breast Cancer at patient treated with fulvestrant and who progressed on or after mTor inhibitor based treatmentpostmenopausal women with hormone receptor-positive, Her2 negative AI and fulvestrant treated, locally advanced or metastatic breast cancer, who progressed on prior fulvestrant and also received prior treatment with everolimus and exemestane. The treatment with fulvestrant is not required to be the last treatment administered as long as at some point in time a progression on fulvestrant has been ascertained.MedDRA version: 14.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2013-000665-36-BEZ Brussel